SALUTENSIN
LOE ApproachingNDAORALTABLET
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALUTENSIN is an oral tablet approved in 1960 by Takeda with unknown mechanism of action and therapeutic indication. As a legacy NDA product approaching loss of exclusivity, it represents a mature asset in Takeda's portfolio with limited clinical development activity.
LOE Approaching
LOE-approaching product with minimal current market engagement; career roles likely focused on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SALUTENSIN has no active linked job openings and limited career development potential as a LOE-approaching product. Roles on this asset are focused on managed decline, market maintenance, and regulatory compliance rather than growth or innovation.
Brand ManagerField Sales
Worked on SALUTENSIN at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.